Effect of B-Type Natriuretic Peptide Level on Long-Term Outcome in Patients With End-Stage Heart Failure

Area of Science:

• Cardiology
• Biomarkers
• Heart Failure Research

Background:

• Elevated B-type natriuretic peptide (BNP) is a known indicator of poor prognosis in heart failure (HF).
• The prognostic impact of low or "normal" BNP levels in end-stage HF remains poorly understood.
• This study investigates BNP levels in patients with dilated cardiomyopathy and end-stage HF.

Purpose of the Study:

• To evaluate the association between B-type natriuretic peptide (BNP) levels and long-term all-cause mortality in patients with end-stage heart failure (HF).
• To explore the prognostic significance of low BNP levels (≤400 pg/ml) in this patient population.

Main Methods:

• Retrospective analysis of 218 consecutive patients with dilated cardiomyopathy and end-stage HF.
• Measurement of admission B-type natriuretic peptide (BNP) levels.
• Median follow-up of 20 months to assess all-cause mortality.

Main Results:

• A significant proportion (28%) of patients presented with low admission BNP levels (≤400 pg/ml).
• Patients with BNP ≤400 pg/ml had a higher all-cause mortality rate (76%) compared to those with BNP >400 pg/ml (48%).
• A U-shaped association was observed between BNP levels and mortality, with both very low (≤400 pg/ml) and very high (>3,000 pg/ml) levels independently predicting increased mortality risk.

Conclusions:

• A "U-like" relationship exists between B-type natriuretic peptide (BNP) levels and all-cause mortality in end-stage heart failure (HF).
• Low BNP levels, often considered "normal," are associated with an increased risk of poor outcome in end-stage HF.
• Low BNP may reflect impaired neurohormonal response or altered BNP metabolism, signifying a critical clinical state.